Estrogen receptor (ER)-positive breast cancer patients may turn ER-negative and develop acquired drug resistance, which compromises the efficacy of endocrine therapy. By investigating the phenomenon that gefitinib can re-sensitise tamoxifen (TAM)-resistant MCF-7 breast cancer cells (MCF-7/TAM) to TAM, the present study verified that gefitinib could reverse the acquired drug resistance in endocrine therapy and further explored the underlying mechanism.ERa-negative MCF-7/TAM cells were established. Upon treating the cells with gefitinib, the mRNA and protein levels of ERa and ERb, as well as the expression of molecules involved in the MAPK pathway, were examined using the RT-PCR and immunocytochemistry. The RT-PCR results showed that the mRNA levels of ERa and ERb in MCF-7/TAM cells were up-regulated following gefitinib treatment; specifically, ERa was re-expressed, and ERb expression was up-regulated. The expression of molecules involved in the MAPK pathway, including RAS, MEK1/2, and p-ERK1/2, in MCF-7/ TAM cells was significantly up-regulated, compared with MCF-7 cells. After the gefitinib treatment, the expression levels of MEK1/2 and p-ERK1/2 were significantly down-regulated. ERa loss is the primary cause for TAM resistance. Gefitinib reverses TAM resistance primarily by up-regulating the ERa mRNA level and inducing the re-expression of ERa. The MAPK pathway plays a key role in ERa re-expression.
A s the primary therapeutic regimen for treating hormone receptor-positive breast cancers, endocrine therapy demonstrates an efficacy of approximately 50-60%. In clinical practice, TAM is the most commonly used endocrine therapeutic drug and has been shown to reduce the relapse and mortality rates of ER-positive breast cancers by 40-50% and 30-35%, respectively 1 . However, primary or acquired drug resistance is the primary cause of the compromised efficacy of endocrine therapy. Approximately 30-50% of ER-positive metastatic breast cancer patients effectively respond to initial TAM treatment. However, almost all patients ultimately develop acquired drug resistance, leading to disease progression or death, which significantly compromises the efficacy of endocrine therapy 2, 3 . Studies of the mechanism underlying endocrine resistance and the corresponding intervention approaches have attracted substantial attention recently. In clinical practice, replacing endocrine therapeutic drugs or switching to chemotherapy is the most common strategy adopted once endocrine resistance has been developed. However, the ER status becomes negative when endocrine resistance occurs; thus, the treatment efficacy cannot be completely restored to the level of the initial treatment by switching to a different endocrine therapeutic drug 4, 5 . Studies have demonstrated that re-expression of the ER, which is the gold standard for selecting patients for endocrine therapy, can re-sensitise breast cancer cells to endocrine therapy 6, 7 . Therefore, searching for approaches to re-express the ER in endocrine resistant cells, investigating the mechanisms underlying ER re-expression, and screening for effective drugs to reverse endocrine resistance are key strategies for enhancing the efficacy of endocrine therapy for breast cancer.
As a small-molecule tyrosine kinase inhibitor, Gefitinib is commonly used in molecularly targeted therapy for lung cancer [8] [9] [10] . Gefitinib has also recently been used in studies of combination endocrine therapy for breast cancer 11, 12 . Endocrine resistance is co-regulated by the signalling networks of both the ER and epidermal growth factor receptor (EGFR), and up-regulation of the MAPK signal converts ER-positive cells into ER-negative cells 13 . Oh et al. found that the transient transfection of MCF-7 cells with active human epidermal growth factor receptor 2 (Her-2), MEK, Raf, or ligand-activated EGFR could down-regulate the mRNA and protein expression of the ER. Moreover, the application of MEK inhibitors was shown to stimulate ER re-expression in breast cancer cells, with these cells subsequently regaining their sensitivity to selective ER antagonists 14 . However, Bayliss et al. demonstrated that ER re-expression does not always result in effective responses to endocrine therapy 15 , as certain cancer cells fail to reexpress ER upon inhibition of the MAPK pathway. Therefore, ER reexpression in ER-negative breast cancer cells for re-sensitisation to endocrine therapy and the mechanism underlying how ER reexpression relates to the MAPK pathway remain crucial questions in endocrine therapy for breast cancers. In addition, the physiological function of estrogen is mediated by both ERa and ERb subtypes. ERa is used not only for drug screening but also for evaluating patient prognosis, and ERa is therefore the gold standard for determining the responsiveness to endocrine therapy for breast cancer 16 . By comparison, the role of ERb in endocrine therapy remains unclear.
In the present study, ERa-negative TAM-resistant MCF-7 breast cancer cells (MCF-7/TAM) were treated with a low dose of Gefitinib to induce ERa re-expression and TAM re-sensitisation. The role of Gefitinib in the mechanism underlying the reversal of endocrine resistance in breast cancer cells was investigated. By exploring this novel clinical application of Gefitinib, the present study sheds new light on reversing endocrine resistance and provides a reference for clinical applications.
Results
Effects of Gefitinib on the proliferation of MCF-7 and MCF-7/ TAM cells. To determine the effects of Gefitinib on the proliferation of MCF-7 and MCF-7/TAM cells, we treated these cells with different doses of Gefitinib for different periods and then used the MTT assay to evaluate cell proliferation ( Figure 1A, B) . The results revealed that treatment with 10 mg/mL Gefitinib for 24 h or 48 h did not inhibit MCF-7/TAM cell proliferation (p . 0.05), whereas treatment with 20 mg/mL Gefitinib for 48 h significantly inhibited cell proliferation. Therefore, to optimise this experiment, a treatment time of 48 h was adopted for subsequent study. The results revealed that Gefitinib at 10 mg/mL did not inhibit MCF-7 and MCF-7/TAM cell proliferation (p . 0.05) and that Gefitinib at a dosage higher than 20 mg/mL inhibited MCF-7 and MCF-7/TAM cell proliferation (p , 0.05). Therefore, we treated cells with Gefitinib at 10 mg/ml for 48 h in the subsequent experiments. CCK-8 for cell proliferation rate ( Figure 1C, D) . As result of MTT, There showed no inhibitory effect on the proliferation of MCF-7/ TAM cells in 24, 48 h with 10 mg/ml Gefitinib (p . 0.05). However There significantly inhibited cell proliferation in 48 h with 20 mg/ml Gefitinib. So 48 h was chosen as the processing time, we found the proliferation of MCF-7 and MCF-7/TAM cells had no inhibitory effect with Gefitinib in the dose of 10 mg/ml (p . 0.05), MCF-7 and MCF-7/TAM cells were inhibited of the proliferation in the above 20 mg/ml dose (p , 0.05). So, we finally determined the dose of 10 mg/ml Gefitinib, treatment time is 48 h to complete the following experiments.
Gefitinib enhanced the sensitivity of MCF-7/TAM cells to TAM. To investigate whether Gefitinib could enhance the sensitivity of MCF-7/TAM cells to TAM, we used 10 mg/mL Gefitinib to treat cells for 48 h and then assessed cell proliferation with the MTT assay ( Figure 2 ). We found that treatment with 10 mg/mL Gefitinib for 48 h re-sensitised MCF-7/TAM cells to TAM, inhibited cell proliferation, and reversed drug resistance.
Gefitinib up-regulated ERa mRNA and ERb mRNA levels in MCF-7/TAM cells. To investigate the mechanism underlying the Gefitinib-mediated reversal of drug resistance in MCF-7/TAM cells, we performed RT-PCR to examine the mRNA levels of ERa and ERb (Figure 3) . The results revealed that, compared with group M0, the mRNA levels of ERa and ERb in the M/T group were downregulated, with the down-regulation of the ERa mRNA level exhibiting a more significant difference (p , 0.05). Following Gefitinib treatment, the ERa mRNA level in the G10 group was significantly up-regulated (p , 0.05), and the ERb mRNA level in the G10 group was also up-regulated (p , 0.05).
Immunocytochemistry and Western blot to determine ERa and ERb expression. The expression levels of ERa in the M0, M/T, and G10 groups were 95.04 6 1.81%, 2.10 6 0.24%, and 75.04 6 2.88%, respectively. The ERb expression levels in each group were 96.13 6 1.07%, 85.13 6 2.17%, and 90.25 6 2.15%, respectively. The results demonstrated that ERa expression in cells from the M/T group was significantly reduced (p , 0.05), and this expression was increased after Gefitinib treatment (p , 0.05). By contrast, the ERb expression level in cells of the M/T group was only slightly decreased (p . 0.05), and Gefitinib treatment increased the ERb expression level ( Figure 4A ). The above results suggest that the TAM resistance of MCF-7 cells is primarily associated with ERa loss, whereas the correlation between ERb expression and TAM resistance is less clear. Western blot analysis for the expression level of ERa and ERb Western blot analysis showed that the expression of, ERa protein levels in M/T group were significantly lower than those of M0 group (p , 0.05). Those treated with 10 mg/ml of Gefitini for the treatment of ERa protein levels were significantly up-regulated after 48 h (p , 0.05). This shows that Gefitini can upregulate the expression of ERa levels, the resistant cells were sensitive to TAM. The chang of ERb protein expression levels is not obvious between Gefitini treatment resistant cells and 10 g/ml Gefitini treatment (p . 0.05) ( Figure 4B ).
Gefitinib down-regulated the expression of signalling molecules in the MAPK pathway. Western blot results showed that the protein expression of molecules involved in the MAPK signalling pathway, including Ras, MEK1/2, and p-ERK1/2, was significantly enhanced in cells of the M/T group compared with the M0 group (p , 0.05). After treatment with 10 mg/mL Gefitinib for 48 h, the protein expression of Ras, MEK1/2, and p-ERK1/2 was reduced compared with the expression levels detected in the M/T group (p , 0.05). These results indicated that Gefitinib could reverse the drug resistance of MCF-7/TAM cells by altering the expression of molecules involved in the MAPK signalling pathway. These results also suggested that the MAPK pathway plays a key role in ERa re-expression ( Figure 5 ).
Discussion
It has been shown that combining Gefitinib with endocrine therapy can delay the development of drug resistance 11, 12 . In addition, our previous study revealed that combining Gefitinib synergistically with TAM inhibits MCF-7 cell proliferation. Studies on the reversal of multi-drug resistance to chemotherapy have demonstrated that drugs with synergistic therapeutic effects play a critical role in the reversal of corresponding drug resistance in chemotherapy 17, 18 . We previously found that elemene (ELE), a traditional Chinese medicine, could reverse the TAM resistance of breast cancer cells and that ERa loss was the primary cause for the development of TAM resistance in these cells. ELE stimulates ERa re-expression by increasing the ERa mRNA level to reverse drug resistance. Moreover, the MAPK pathway is known to be the key signalling pathway involved in ERa reexpression 7 . In the present study, we used established MCF-7/TAM cells to investigate whether Gefitinib could reverse TAM resistance and to explore the underlying mechanism.
A positive ER status is an important prerequisite for endocrine therapy in breast cancer patients. The ER regulates gene transcription through the MAPK pathway 7, 19 , and ER-negative breast cancer cells and resistant breast cancer cells that become ER negative frequently exhibit active MAPK signal transduction pathways [20] [21] [22] . However, the mechanism underlying the reduced ER expression mediated by MAPK up-regulation remains unclear. Certain reports have proposed that both the MAPK pathway and NF-KB contribute to the loss of ER expression 23, 24 . Gefitinib has been shown to downregulate the expression of molecules involved in the MAPK pathway 25, 26 , and our study demonstrated that Gefitinib at a low dose could reverse TAM resistance. We also examined the protein groups, respectively. Sections 2a-2c represent ERb expression in the M0, M/T, and G10 groups, respectively. ERa expression in cells of the M/T group was rarely observed. ERa was re-expressed in cells of the G10 group after treatment with 10 mg/mL Gefitinibfor 48 h. The ERb expression in cells of the M/T group was also slightly down-regulated. These data were obtained from 3 independent experiments (DAB staining, 3400). (B): The expression of ERa in M/T group were significantly reduced than M0 group, with10 mg/ml Gefitini treatment for 48 h, the change of ERb protein expression level is not obvious. All the experiments were repeated three times. *denotes p , 0.05. expression of MAPK pathway molecules, including Ras, MEK1/2, and P-ERK1/2ER, and found that MEK1/2 and P-ERK1/2ER expression levels in the M/T group were enhanced compared with the expression levels observed in the M0 group. Furthermore, treatment with Gefitinib significantly reduced the protein levels of these pathway components, suggesting that Gefitinib may reverse drug resistance in MCF-7/TAM cells by altering the expression of molecules involved in the MAPK pathway. Gefitinib was also shown to up-regulate the ERa mRNA level and induce ERa re-expression. Although this drug also increased the ERb mRNA level, the association between ERb expression and endocrine resistance remains unclear. Changes in the expression of molecules involved in the MAPK pathway affect both ERa and ERb expression, and ERa reexpression mainly re-sensitises drug-resistant cells to TAM. Although the ERb mRNA level was significantly increased in the G10 group, the change in ERb protein expression was mild. Moreover, the ERb expression in drug-resistant cells remained at a relatively high level. Treatment with Gefitinib increased both the mRNA and protein levels of ERa and ERb in the G10 group compared with the M/T group, and the ERa/ERb ratio in the G10 group was also higher than that observed in the M/T group. Consequently, the G10 group demonstrating a higher ratio of ERa/ERb regained sensitivity to TAM. These results suggest that both ERa and ERb are involved in the development of drug resistance and that their ratio may indicate sensitivity to endocrine therapy 27 . In our previous study of ELE, we used the ERa mRNA/ERb mRNA ratio as a criterion and found that ELE treatment yielded a ratio value greater than 1, suggesting that the effects on the ERa mRNA levels were significant. We also found that Gefitinib treatment yielded a ratio value less than 1, suggesting that the effects on ERb mRNA levels were also significant 7 . Both ELE and Gefitinib treatments led to the reversal of drug resistance, indicating that the down-regulation of the ERa protein affects drug resistance, whereas the role of ERb expression in drug resistance remains unclear. Indeed, ERb may represent a new therapeutic target in endocrine-resistant cells, although further studies are required to investigate this potential. In addition, compared with our previous results for ELE, the changes in the ERb mRNA level after Gefitinib treatment in the present study were significantly higher than those observed after ELE treatment. ERb expression does not require a high mRNA level. Thus, it is possible that, in addition to affecting the MAPK pathway, Gefitinib is also involved in regulating transcription by other pathways; moreover, ERb might play an important role in the proliferation of drug resistant cells. However, reports on the role of ERb in endocrine resistance have been contradictory. Gruvberger et al. 28 found that, in ERa-negative breast cancer patients, ERb expression served as an independent prognostic factor, and such patients benefitted from TAM therapy with a significantly reduced relapse rate. Peach et al. 29 reported that ERa activates transcription at the AP-1 site in an estradiol (E2)-dependent manner and that such activity was lost following treatment with an anti-estrogen. In contrast with ERa, the binding of ERb to E2 does not activate transcription; instead, the binding to TAM stimulates transcription at the AP-1 site and induces cell proliferation. Hodges et al. 30 proposed that TAM may block cell proliferation by inhibiting cyclin D1. Furthermore, the stimulation of transcription at AP-1 sites by the binding of ERb and TAM is thought to provide a mechanism to explain how ERb expression leads to TAM resistance. However, Strom et al. 31 induced ERb expression in T47D cells and found that neither E2 nor TAM could stimulate cell proliferation. According to other reports, a low level of ERb may be a preliminary sign of TAM resistance 32, 33 . Thus, these inconsistent results show that the role of ERb in endocrine resistance remains inconclusive, and our study also failed to clarify the effects of ERb on endocrine resistance.
Another mechanism underlying the conversion to ERa negative status is methylation of the CpG island in the promoter region of the ERa gene, in addition to histone deacetylation [34] [35] [36] . Overexpressed histone deacetylase (HDAC) was shown to convert ERa-positive MCF-7 cells into ERa-negative cells, whereas HDAC inhibitors restored these cells to an ERa-positive status 37 . In addition, Shen et al. found that DNA methylation inhibitors could induce ER-negative breast cancer cells to re-express active ER in nude mice 38 . In our study, MCF-7/TAM cells demonstrated low levels of ERa mRNA and the almost complete absence of ER protein expression. Whether ER gene silencing occurred in our experiments was not investigated. Therefore, in addition to altering the expression of molecules involved in the MAPK pathway to stimulate ER reexpression, whether Gefitinib inhibits DNA methylation or inhibits histone deacetylation requires further investigation.
The mechanisms underlying endocrine resistance are extremely complex, which provides many avenues for analysis. Indeed, endocrine therapy combined with Gefitinib, lapatinib, or everolimus is currently under investigation in clinical trials, and initial results have revealed that combination therapy may improve the progression and clinical benefit in treated patients 6, 39, 40 . Our investigation demonstrated that Gefitinib could reverse TAM resistance in breast cancer cells by inducing ERa re-expression. In terms of clinical applications, our results may allow patients who have already developed acquired drug resistance to benefit from re-exposure to endocrine therapy. Thus, we believe that our study will provide a novel therapeutic target and strategy for endocrine therapy. Methods Cell culture. MCF-7 cells (Shanghai, ChineseAcademy of Sciences Cell Repository) were cultured in DMEM/H-G media (USA, GIBCO) containing 10% fetal bovine serum (FBS) (GIBCO, USA). MCF-7/TAM cells (TRC, Canada) were cultured in complete DMEM/H-G containing 1.0 3 10 27 mol/L TAM for 6 months 41 . After drug resistance was established, the cells were cultured in DMEM/H-G media containing 10% FBS. The MCF-7/TAM cells were treated with 10 mg/mL or 20 mg/mL Gefitinib (AstraZeneca, USA) for 48 h. The experiments consisted of the following groups: the MCF-7 group (M0), the MCF-7/TAM group (M/T), and the MCF-7/TAM-Gefitinib (10 mg/ml) group (G10). Cell culture was performed at 37uC and 5% CO 2 , and the cells were passaged every 3-4 days.
MTT assay to determine viability. The cells were trypsinised with 0.25% trypsin (GIBCO, USA) and seeded into 96-well tissue culture plates at a density of 1 3 10 4 cells/mL and 100 mL per well. The cells were cultured at 37uC and 5% CO 2 for 24 h. In total, 100 mL of culture medium containing a predetermined concentration gradient of Gefitinib or TAM was added, and the same type of medium was added to the control wells. Each treatment group contained 4 wells. After a 48-h incubation, 20 mL MTT (0.5 mg/mL) was added to each well. The cells were incubated at 37uC for 4 h, and then 200 mL DMSO was added. The plate was shaken for 15 min, and the absorbance values of each cell were measured at 492 nm using an enzyme-linked immunosorbent assay (ELISA) analyser 42 .
CCK8 cell viability assay. Cell viability was assessed by a Cell counting Kit-8 (CCK8) assay (KeyGEN BioTECH, China). Cells (1 3 10 4 cells/well) were plated into 96-well plates. After 24 h, the cells were treated with different concentrations of Gefitinib (0-40 mg/mL) or TAM (1.5 mmol/L) or DMSO (0.1%). After incubation with for 24 h, 48 h or 72 h, the CCK8 reagent was added to each well and cells were incubated for 2 h at 37uC. The absorbance (optical density) at 450 nm was measured.
Immunocytochemistry. The drop plate method was used. Cells were collected and trypsinised to produce a single-cell suspension. The cell density was adjusted to 1.0 3 10 6 cells/mL, and the cells were fixed with methanol for 20 min. Next, 10 mL of the cell suspension was placed onto poly-L-lysine-coated glass slides. The staining was performed according to the kit manual (the ERa and ERb antibodies, ready-to-use SP kit, and concentrated DAB colour development kit were obtained from Beijing, Zhongshan Golden Bridge Biotechnology Co., Ltd.). The slides were treated with 0.5% Triton X-100 (in an ice-water bath) for 5 min, washed with PBS for 3 3 2 min, treated with 3% H 2 O 2 (room temperature) for 15 min, washed again with PBS for 3 3 2 min, and blocked with the blocking serum provided in the kit at 37uC for 20 min. The slides were then incubated with the primary antibody (or with PBS for the control group) at 4uC overnight. The slides were kept at room temperature for 1 h, washed with PBS for 3 3 2 min, incubated with the secondary antibody at 37uC for 20 min, and washed with PBS for 3 3 2 min. The slides were then incubated with streptavidin-biotin complex (SABC) at 37uC in a moisturised chamber for 20 min and washed with PBS for 3 3 4 min. Next, the slides were stained with 3, 39-diaminobenzidine (DAB)and were washed with tap water. Subsequently, the slides were stained with haematoxylin for 2-5 s, dehydrated, mounted, and then observed under a microscope.
Reverse transcription polymerase chain reaction (RT-PCR). Cells were collected by centrifugation, and RNA was extracted using the Trizol method (TaKaRa, Dalian, China). The total RNA concentration was calculated. The following primers were designed according to previous reports 7, 43 : ERa-forward: AATTCAGATAATC-GACGCCAG, ERa-reverse: GTGTTTCAACATTCTCCCTCCTC; ERb-forward: TAGTGGTCCATCGCCAGTTAT, ERb-reverse: GGGAGCCAACACTTCACCAT; and GAPDH-forward: 59-ACCACAGTCCATGCCATCAC-3, GAPDH-reverse: 59-TCCACCACCCTGTTGCTGTA-39. RT-PCR was performed according to the kit manual (TaKaRa, Dalian, China). The volume of each PCR reaction was 50 mL. The cycling conditions consisted of 94uC for 5 min, followed by 30 cycles of 94uC for 45 s for denaturing, 60uC for 45 s for annealling, and 72uC for 1 min for elongation. The PCR product was analysed using 1.5% agarose gel electrophoresis. A gel imaging system was used to scan the agarose gel.
Western blot. Cells were collected and washed twice with PBS, and 2 mL lysate buffer (50 mM Tris-HCl, 137 mM NaCl, 10% glycerol, 100 mM sodium vanadate, 1 mM PMSF, 10 mg/mL aprotinin, 10 mg/mL leupeptin, and 1% NP-40; 5 mM cocktail; pH 7.4) was added to lyse the cells. The cell lysate was then centrifuged at 4uC and 25,000 rpm for 30 min, and the supernatant was collected. The protein concentration was determined using the bicinchoninic acid assay (BCA). The protein sample was dyed with bromophenol blue, and the same amount of protein was loaded into each well of a 10% SDS-PAGE gel. The separated protein on the gel was transferred to a polyvinylidenedifluoride (PVDF) membrane using the semi-dry transfer method. The membrane was blocked in 5% skim milk overnight. On the next day, the membrane was washed with tris-buffered saline and tween 20 (TBST) and then incubated with rabbit anti human monoclonal antibodies at 37uC for 1 h (anti-ERa and anti-ERb:USA, Bioworld; anti-Ras: USA, Proteintech Group; anti-MEK1/2 and anti-p-ERK1/2: USA, Bioworld). The antibodies were diluted 15500. The membrane was then washed with TBST and incubated with a horseradish peroxidase-conjugated goat anti-rabbit IgG secondary polyclonal antibody at 37uC for 1 h (Beijing, Zhongshan Golden Bridge Biotechnology Co., Ltd.). The signal was developed by adding chemiluminescence reagents, followed by exposure on X-ray film. The image was scanned and analysed by densitometry.
Statistical analysis. The data were analysed using the SPSS 16.0 statistical analysis software. Variance analysis was performed on 3 groups of data. The chi-square test was performed on the categorical data. Numeric data are presented as the mean 6 standard deviation. p , 0.05 represents a statistically significant difference.
